Page 643 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 28 Tumors of the Mammary Gland 621

30. Schafer KA, Kelly G, Schrader R, et al.: A canine model of familial 53. van Garderen E, Schalken JA: Morphogenic and tumorigenic
mammary gland neoplasia, Vet Pathol 35:168–177, 1998. potentials of the mammary growth hormone/growth hormone
31. Ford D, Easton DF, Stratton M, et al.: Genetic heterogeneity and receptor system, Mol Cell Endocrinol 197:153–165, 2002.
VetBooks.ir penetrance analysis of the BRCA1 and BRCA2 genes in breast 54. Mol JA, Selman PJ, Sprang EP, et al.: The role of progestins, insu-
lin-like growth factor (IGF) and IGF-binding proteins in the nor-
cancer families. The breast cancer linkage consortium, Am J Hum
Genet 62:676–689, 1998.
Fertil Suppl 51:339–344, 1997.
32. King MC, Marks JH, Mandell JB: Breast and ovarian cancer mal and neoplastic mammary gland of the bitch: a review, J Reprod
risks due to inherited mutations in BRCA1 and BRCA2, Science 55. Hamelers IH, van Schaik RF, van Teeffelen HA, et al.: Synergis-
302:643–646, 2003. tic proliferative action of insulin-like growth factor 1 and 17 beta-
33. Easton DF, Ford D, Bishop DT: Breast and ovarian cancer inci- estradiol in MCF-7s breast tumor cells, Exp Cell Res 273:107–117,
dence in BRCA1–mutation carriers. Breast cancer linkage consor- 2002.
tium, Am J Hum Genet 56:265–271, 1995. 56. Thorne C, Lee AV: Cross talk between estrogen receptor and IGF
34. Fackenthal JD, Olopade OI: Breast cancer risk associated with signaling in normal mammary gland development and breast can-
BRCA1 and BRCA2 in diverse populations, Nat Rev Cancer 7:937– cer, Breast Dis 17:105–114, 2003.
948, 2007. 57. Laban C, Bustin SA, Jenkins PJ: The GH-IGF-i axis and breast
35. Klopfleisch R, Gruber AD: Increased expression of BRCA2 and cancer, Trends Endocrinol Metab 14:28–34, 2003.
Rad51 in lymph node metastases of canine mammary adenocarci- 58. van der Burg B, Rutteman GR, Blankenstein MA, et al.: Mitogenic
nomas, Vet Pathol 46:416–422, 2009. stimulation of human breast cancer cells in a growth factor-defined
36. Nieto A, Perez-Alenza MD, Del Castillo N, et al.: BRCA1 medium: synergistic action of insulin and estrogen, J Cell Physiol
expression in canine mammary dysplasias and tumours: rela- 134:101–108, 1988.
tionship with prognostic variables, J Comp Pathol 128:260–268, 59. Osborne CK, Clemmons DR, Arteaga CL: Regulation of breast
2003. cancer growth by insulin-like growth factors, J Steroid Biochem Mol
37. Perez Alenza D, Rutteman GR, Pena L, et al.: Relation between Biol 37:805–809, 1990.
habitual diet and canine mammary tumors in a case-control study, 60. Dupont J, Le Roith D: Insulin-like growth factor 1 and oestra-
J Vet Intern Med 12:132–139, 1998. diol promote cell proliferation of MCF-7 breast cancer cells: new
38. Calle EE, Kaaks R: Overweight, obesity and cancer: epidemiologi- insights into their synergistic effects, Mol Pathol 54:149–154, 2001.
cal evidence and proposed mechanisms, Nat Rev Cancer 4:579– 61. Queiroga FL, Perez-Alenza D, Silvan G, et al.: Serum and intra-
591, 2004. tumoural GH and IGF-i concentrations: prognostic factors in
39. Carmichael AR, Bates T: Obesity and breast cancer: a review of the the outcome of canine mammary cancer, Res Vet Sci 89:396–403,
literature, Breast 13:85–92, 2004. 2010.
40. Tymchuk CN, Tessler SB, Barnard RJ: Changes in sex hormone- 62. Queiroga FL, Perez-Alenza MD, Silvan G, et al.: Crosstalk between
binding globulin, insulin, and serum lipids in postmenopausal GH/IGF-1 axis and steroid hormones (progesterone, 17beta-
women on a low-fat, high-fiber diet combined with exercise, Nutr estradiol) in canine mammary tumours, J Steroid Biochem Mol Biol
Cancer 38:158–162, 2000. 110:76–82, 2008.
41. Wu AH, Pike MC, Stram DO: Meta-analysis: dietary fat intake, 63. Klopfleisch R, von Euler H, Sarli G, et al.: Molecular carcinogen-
serum estrogen levels, and the risk of breast cancer, J Natl Cancer esis of canine mammary tumors: news from an old disease, Vet
Inst 91:529–534, 1999. Pathol 48:98–116, 2011.
42. Hankinson SE, Willett WC, Manson JE, et al.: Plasma sex ste- 64. Rivera P, von Euler H: Molecular biological aspects on canine and
roid hormone levels and risk of breast cancer in postmenopausal human mammary tumors, Vet Pathol 48:132–146, 2011.
women, J Natl Cancer Inst 90:1292–1299, 1998. 65. Gilbertson SR, Kurzman ID, Zachrau RE, et al.: Canine mammary
43. Cleary MP, Grossmann ME: Minireview: obesity and breast epithelial neoplasms: biologic implications of morphologic charac-
cancer: the estrogen connection, Endocrinology 150:2537–2542, teristics assessed in 232 dogs, Vet Pathol 20:127–142, 1983.
2009. 66. Moulton JE, Rosenblatt LS, Goldman M: Mammary tumors in a
44. Cleary MP, Grossmann ME, Ray A: Effect of obesity on breast colony of beagle dogs, Vet Pathol 23:741–749, 1986.
cancer development, Vet Pathol 47:202–213, 2010. 67. Bender AP, Dorn CR, Schneider R: An epidemiologic study of
45. Rehm S, Stanislaus DJ, Williams AM: Estrous cycle-dependent his- canine multiple primary neoplasma involving the female and male
tology and review of sex steroid receptor expression in dog repro- reproductive systems, Prev Vet Med 2:715–731, 1984.
ductive tissues and mammary gland and associated hormone levels, 68. Antuofermo E, Miller MA, Pirino S, et al.: Spontaneous mammary
Birth Defects Res B Dev Reprod Toxicol 80:233–245, 2007. intraepithelial lesions in dogs—a model of breast cancer, Cancer
46. Santos M, Marcos R, Faustino AM: Histological study of canine Epidemiol Biomarkers Prev 16:2247–2256, 2007.
mammary gland during the oestrous cycle, Reprod Domest Anim 69. MacEwen EG, Patnaik AK, Harvey HJ, et al.: Estrogen receptors in
45:e146–154, 2010. canine mammary tumors, Cancer Res 42:2255–2259, 1982.
47. Pike MC, Spicer DV, Dahmoush L, et al.: Estrogens, progestogens, 70. Rutteman GR, Misdorp W, Blankenstein MA, et al.: OEstrogen
normal breast cell proliferation, and breast cancer risk, Epidemiol (ER) and progestin receptors (PR) in mammary tissue of the female
Rev 15:17–35, 1993. dog: different receptor profile in non-malignant and malignant
48. Russo J, Russo IH: The role of estrogen in the initiation of breast states, Br J Cancer 58:594–599, 1988.
cancer, J Steroid Biochem Mol Biol 102:89–96, 2006. 71. Illera JC, Perez-Alenza MD, Nieto A, et al.: Steroids and receptors
49. Okoh V, Deoraj A, Roy D: Estrogen-induced reactive oxygen spe- in canine mammary cancer, Steroids 71:541–548, 2006.
cies-mediated signalings contribute to breast cancer, Biochim Bio- 72. Millanta F, Calandrella M, Bari G, et al.: Comparison of steroid
phys Acta 1815:115–133, 2011. receptor expression in normal, dysplastic, and neoplastic canine
50. Dickson RB, Lippman ME, Slamon D: UCLA colloquium. New and feline mammary tissues, Res Vet Sci 79:225–232, 2005.
insights into breast cancer: the molecular biochemical and cellular 73. Donnay I, Rauis J, Devleeschouwer N, et al.: Comparison of estro-
biology of breast cancer, Cancer Res 50:4446–4447, 1990. gen and progesterone receptor expression in normal and tumor
51. Mol JA, Lantinga-van Leeuwen IS, van Garderen E, et al.: Mam- mammary tissues from dogs, Am J Vet Res 56:1188–1194, 1995.
mary growth hormone and tumorigenesis—lessons from the dog, 74. de Las Mulas JM, Millan Y, Dios R: A prospective analysis of
Vet Q 21:111–115, 1999. immunohistochemically determined estrogen receptor alpha and
52. Selman PJ, Mol JA, Rutteman GR, et al.: Progestin-induced growth progesterone receptor expression and host and tumor factors as
hormone excess in the dog originates in the mammary gland, Endo- predictors of disease-free period in mammary tumors of the dog,
crinology 134:287–292, 1994. Vet Pathol 42:200–212, 2005.